Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Stopped early · Phase 3

Conditions studied: Anemia, Cancer

In brief

The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.

Key facts

Study ID

NCT00083434

Run by

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Starts

2004-02-01

Expected to finish

2004-10-01

Last updated by the study team

2011-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Body weight >/= 99lbs
• ECOG 0-2
• Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
• Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women

You may not qualify if…

• History of or concurrent second malignancy
• Evidence of primary or metastatic malignancy involving the Central Nervous System

Where it is running

• Advanced Urology Medical Center — Anaheim, California, United States
• Shapiro, Stafford & Yee — Arcadia, California, United States
• California Cancer Center — Fresno, California, United States
• Tukoi Research — North Miami, Florida, United States
• Hanover Medical Specialists, PA — Wilmington, North Carolina, United States
• Madigan Army Medical Center Urology Services — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.